These advanced-level courses present balanced, timely, scientifically rigorous, and clinically relevant information about HIV and other viral diseases. The activities are designed for physicians who are actively involved in viral disease management.
HIV Medicine Association has compiled HIV training opportunities for medical students and clinical fellows. Some may require fees, including registration, travel and/or housing costs.
HRSA’s AIDS Education and Training Center (AETC) Program supports national HIV priorities by building clinician and care team capacity and expertise along the HIV care continuum. The AETC Program is a national network of leading HIV experts who provide locally-based, tailored education, clinical consultation and technical assistance to healthcare professionals and healthcare organizations to integrate high quality, comprehensive care for those living with or affected by HIV.
August 13, 2019
Dr. Oliver Bacon facilitates an audience-led panel discussion with PrEP Experts and covers the following learning objectives for this webinar:
Video example of a disease intervention interview linking a person co-infected with syphilis and HIV to care, and providing partner services.
Example of a disease intervention interview linking a person newly diagnosed with HIV to care, conducted by telephone.
On hold due to COVID-19. Will resume as soon as it is safe to do so.
Stigma has been a major obstacle in combating HIV since the beginning of the epidemic. The communities in the United States disproportionately impacted by HIV are those historically impacted by other types of stigma based on factors such as race/ethnicity, sexual orientation, gender identity, age, and socio-economic status.
A comprehensive response to stigma is needed in order to impact current health disparities and improve engagement at all levels of HIV treatment and care.
This course examines the sources and repercussions of stigma. It focuses on changes providers can make to respond to the impact that stigma has on risk, prevalence, and access to services.
This training is appropriate for any providers working in HIV prevention or treatment.
Director of the CAPTC Dana Cropper sits down with Gail Bolan, MD, and Alice Gandelman to discuss the founding of the CAPTC and its work in supporting sexual healthcare providers over the last 33 years. We learn about the forces that shaped the sexual healthcare field. Our guests unpack how the CAPTC developed alongside the HIV/AIDS epidemic in the late 1980s, the surprising relationship between HIV work and STI response, strategies to meet sexual healthcare needs both within and outside of sexual health clinics, and the ever-present need for greater training for providers around testing and treatment of STIs. We learn about how behavioral interventions were centered in response to the HIV/AIDS epidemic, and the importance of centering social determinants of health and larger structural forces in prevention and treatment efforts. They also discuss their hopes for opening up discussions about sexual health and de-stigmatizing the topic in the greater community.
Read the transcript of the episode here.
Resources:
HHS/Viral Hepatitis Action Plan
Ending the HIV Epidemic in the US (EHE)
Provision of Quality of STD Services (CDC) 2020
National Coalition for Sexual Health
Turn on notifications to never miss an episode of Coming Together for Sexual Health.
Follow Coming Together for Sexual Health on Instagram and Twitter.
Gail Bolan, MD, was the Director of the Division of STD Prevention at the Centers for Disease Control and Prevention (CDC) from 2011 through 2020. Prior to joining CDC, she directed the California Prevention Training Center for 23 years. She served as the Chief of the STD Control Branch at the California Department of Public Health and the Director of the San Francisco City and County STD Prevention and Control Program from 1997 to 2011 as well as Medical Director of the San Francisco City Clinic from 1987 to 1997.
Alice Gandelman was the Director of the CAPTC from 1994 through 2021. She oversaw growth and development of CAPTC in numerous training and capacity-building programs in STD, HIV, sexual, and reproductive health.
We speak with Terrance Wilder and Nikole Trainor, two people who were intimately involved in PrEP Supports, a campaign launched by the San Francisco Department of Public Health in 2018. PrEP Supports was a community-engaged campaign that specifically focused on PrEP access and education in Black communities in San Francisco.
Download the transcript of this episode.
Resources from Terrance, Nikole, and the CAPTC:
Turn on notifications to never miss an episode of Coming Together for Sexual Health.
Follow Coming Together for Sexual Health on Instagram and Twitter
Terrance Wilder is an Equity Training Coordinator at the San Francisco AIDS Foundation where he’s worked for 5 years. In addition to putting in work at SFAF, Terrance is an avid basketball player, hiker, and comedy fan.
Nikole Trainor currently works full-time for the San Francisco Department of Public Health (SFDPH) as the Getting to Zero Program Coordinator/Contract Manager, while also teaching part-time at SJSU in the School of Public Health. Nikole has worked for SFDPH in the STD Prevention and Control Branch for the past 13 years. She is responsible for spearheading several innovative initiatives which included the launch of the San Francisco PrEP Supports Campaign (2019), launch of Have Good Sex Campaign (2020), implementation of the first Pharmacist Delivered One-Stop PrEP Program at Mission Wellness Pharmacy in San Francisco CA (2018-present), and the implementation of the first official lab-based HIV/STI/HCV home-testing program (2021). For the past 15 years, Nikole has been dedicated to improving quality of life for all communities of color and speaking boldly about inequities that negatively impact the communities in which she serves.
On Jan 21, 2021, the FDA approved Cabenuva, the first once-monthly injectable HIV treatment for adults. Dr. Kelly Johnson, a fellow in infectious diseases and in sexually transmitted diseases at the University of California, San Francisco, explains the implications of this new treatment and how it affects the 1.2 million Americans living with HIV.
